Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Van Wagoner
David R
DR
Nattel
Stanley
S
D000804:Angiotensin II / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001281:Atrial Fibrillation / Q000139:chemically induced / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D006332:Cardiomegaly / Q000151:congenital / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D017630:Connexins / Q000235:genetics / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D005355:Fibrosis; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism*; D018398:Homeodomain Proteins / Q000096:biosynthesis* / Q000235:genetics; D006877:Hydroxamic Acids / Q000009:adverse effects* / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic; D013997:Time Factors; D000097003:Gap Junction alpha-5 Protein
D000804:Angiotensin II; D017630:Connexins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases; D018398:Homeodomain Proteins; D006877:Hydroxamic Acids; D000097003:Gap Junction alpha-5 Protein; C466740:Hop protein, mouse; C012589:trichostatin A